Skip to main content
Fig. 5 | Infectious Agents and Cancer

Fig. 5

From: Bimodal antibody-titer decline following BNT162b2 mRNA anti-SARS-CoV-2 vaccination in healthcare workers of the INT – IRCCS “Fondazione Pascale” Cancer Center (Naples, Italy)

Fig. 5

a Vaccine immune response increase after boost dose administration in not previously infected healthcare providers’ diluted samples. T0 = baseline pre-vaccination, T1 = 20 days after the first dose, T2 I = 8 days after the second dose, T2 II = 1 month after the second dose, T3 = 3 months after the second dose, T6 = 6 months after the second dose, T9 = 9 months after the second dose, T boost = 8 days after the administration of a further boost dose. Each colored line represents a subject. b Vaccine immune response increase after boost dose administration in previously infected healthcare providers’ diluted samples. T0 = baseline pre-vaccination after SARS-CoV-2 infection, T1 = 8 days after the unique dose, T2 = 1 month after the unique dose, T3 = 3 months after the unique dose, T6 = 6 months after the unique dose, T9 = 9 months after the unique dose, T boost = 8 days after the administration of a further boost dose. Each colored line represents a subject

Back to article page

Infectious Agents and Cancer

ISSN: 1750-9378

Contact us